Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
0
Authors
Adel Samson
Adel Samson•Karen Scott•Alan Melcher
Published
January 3, 2018
Abstract
Intravenous infusion of oncolytic reovirus in patients leads to infection of brain tumors, infiltration by cytotoxic T cells, and up-regulation of PD-L1.
